Ipamorelin

Research literature on growth hormone secretagogues

Research suggests that administering Ipamorelin before bed may capitalize on the body's natural nocturnal GH pulse. Dosing multiple times a day may aim to maintain elevated GH levels, though the exact optimal frequency is a subject of ongoing research.

• CJC-1295 (without DAC)

  CJC-1295 (without DAC) is a GHRH analog that stimulates the production and release of GH. When combined with Ipamorelin (a GHS-R agonist), a synergistic effect is observed, leading to a more pronounced and sustained pulsatile GH release, often referred to as a 'GH stack' in research contexts.

  Synergistic

• Macromorelin (MK-677)

  Macromorelin is an oral GHS that has a significantly longer half-life. While both stimulate GH, combining them may lead to excessive GH and IGF-1 levels. Research protocols are scarce on this combination, and caution is advised due to the potential for compounding side effects associated with chronically elevated GH.

  Monitor Combination

• Exogenous Growth Hormone (hGH)

  Combining Ipamorelin with exogenous hGH could lead to supraphysiological levels of GH, which may increase the risk of side effects such as insulin resistance, carpal tunnel syndrome, and acromegaly-like symptoms. This combination is generally not explored in protocols aiming for physiological GH regulation.

  Use Caution

• Somatostatin (Growth Hormone-Inhibiting Hormone)

  Somatostatin naturally inhibits GH release. Any compound that significantly increases somatostatin levels or acts as a somatostatin analog would counteract the effects of Ipamorelin, making the combination counterproductive.

  Avoid

• Glucocorticoids (e.g., Dexamethasone)

  Glucocorticoids can suppress GH secretion and blunt the response to GHRH and GHS. Concurrent use might diminish the efficacy of Ipamorelin. Research suggests a need for careful monitoring if these compounds are co-administered.

  Use Caution

• Insulin

  GH can have an anti-insulin effect, potentially increasing blood glucose. While Ipamorelin is noted for its clean profile, individuals using insulin (especially diabetics) should monitor blood glucose levels closely if Ipamorelin is part of a research protocol, as GH elevation could impact insulin sensitivity.

  Monitor Combination

1. 1Gather necessary supplies: Ipamorelin vial, bacteriostatic water, sterile syringe, and alcohol wipes.
2. 2Remove the protective cap from the Ipamorelin vial and wipe the rubber stopper with an alcohol wipe.
3. 3Draw the desired amount of bacteriostatic water into the syringe. A common ratio is 1ml (100 units on an insulin syringe) of water per 2mg of peptide, but this can vary.
4. 4Slowly inject the bacteriostatic water into the Ipamorelin vial, aiming the needle towards the side of the vial to allow the water to run down gently, avoiding direct injection onto the lyophilized powder.
5. 5Do not shake the vial. Gently swirl the vial between your fingers until the powder is fully dissolved. This may take several minutes.
6. 6Once dissolved, the solution should be clear. Store the reconstituted solution in the refrigerator.

Bacteriostatic water is commonly discussed for reconstitution to ensure sterility and extend shelf life.

• Weeks 1-2: Some individuals may report improved sleep quality and a general sense of well-being.
• Weeks 2-4: Early signs of improved recovery from physical activity may be observed. Appetite changes might also be noted due to ghrelin receptor activation.
• Weeks 4-8: More consistent improvements in recovery and potentially subtle changes in body composition (e.g., slight reductions in body fat, increased lean mass) may become apparent.
• Weeks 8-12: The most significant changes in body composition, including enhanced lean muscle development and fat loss, are typically observed during this period, assuming consistent protocol adherence.
• Post-cycle: Maintenance of benefits often requires continued healthy lifestyle choices, as the peptide primarily stimulates endogenous GH release rather than exogenously supplying it.